What are the clinical features, diagnostic criteria, and first-line treatment for mast cell activation syndrome?

Mast Cell Activation Syndrome: Clinical Features and Management

Diagnostic Criteria

Mast Cell Activation Syndrome requires simultaneous fulfillment of three mandatory criteria: (1) recurrent episodic symptoms affecting at least two organ systems concurrently, (2) documented elevation of mast cell mediators on at least two separate symptomatic episodes, and (3) demonstrable clinical improvement with mast cell-targeted therapy. 1, 2, 3, 4

Clinical Features by Organ System

Dermatologic manifestations:

• Urticaria, pruritus, and flushing occur in 20-65% of patients 1, 2
• Angioedema, particularly of eyelids, lips, and tongue 1
• Darier's sign (urtication after rubbing) may be present in cutaneous mastocytosis but is not universal 2

Cardiovascular manifestations:

• Hypotension, tachycardia, syncope or near-syncope 1, 3
• Hypotensive episodes can be life-threatening and require immediate supine positioning 2

Gastrointestinal manifestations:

• Abdominal cramping, diarrhea, nausea, and vomiting affect up to 40% of patients 1, 2
• Symptoms often mimic irritable bowel syndrome 2

Respiratory manifestations:

• Wheezing, shortness of breath, and inspiratory stridor 1, 3
• Bronchospasm from mast cell mediator release 2

Neurologic manifestations:

• Headache and cognitive dysfunction ("brain fog") 3

Critical Diagnostic Pitfalls

MCAS is substantially overdiagnosed when:

• Only a single organ system is involved 1, 4
• Symptoms are chronic and persistent rather than episodic 1, 4
• Mediator elevation is not documented 4
• No therapeutic response to appropriately dosed mast cell-targeted agents occurs 4

Laboratory Confirmation

Serum Tryptase (Primary Biomarker)

Obtain baseline serum tryptase when the patient is completely asymptomatic to establish a personal reference value. 1, 2, 3, 4

During a suspected episode, collect acute serum tryptase 1-4 hours (optimal 30-120 minutes) after symptom onset. 1, 2, 3, 4

The diagnostic threshold is an increase ≥20% above the patient's baseline PLUS an absolute increase ≥2 ng/mL, and this elevation must be documented on at least two separate occasions. 1, 2, 3, 4

Urine Mediator Testing (When Tryptase Unavailable or Negative)

Perform 24-hour urine collection for:

• N-methylhistamine (preferred over direct plasma/serum histamine) 1, 2, 4
• Leukotriene E4 (LTE4) peaks 0-6 hours after episodes and guides leukotriene antagonist therapy 1, 2, 4
• 11β-prostaglandin F2α peaks 0-3 hours, correlates with anaphylactic severity, and suggests potential aspirin benefit 1, 2, 4

Tests NOT Recommended

• Plasma or urine histamine levels (use N-methylhistamine instead) 2
• Heparin (not validated as a marker) 2
• Chromogranin A (resides in neuroendocrine cells, not mast cells) 2

Subtype Classification

Primary (Clonal) MCAS

Peripheral blood KIT D816V mutation testing using highly sensitive allele-specific oligonucleotide quantitative PCR (ASO-qPCR) identifies clonal mast cell disease. 2, 3, 4

Buccal swab for TPSAB1 α-tryptase copy number variation diagnoses hereditary α-tryptasemia, a genetic condition with chronically elevated baseline tryptase. 2, 4

Bone marrow biopsy is indicated when:

• Baseline tryptase persistently >20 ng/mL 2, 3, 4
• Clinical features suggest systemic mastocytosis (adult-onset urticaria pigmentosa, organomegaly, cytopenias) 2, 4
• KIT testing is negative but suspicion remains high 4

Secondary MCAS

Normal mast cells activated by identifiable external triggers (allergens, physical stimuli, drugs, infections); no KIT mutations or aberrant CD25 expression. 3, 5

Systematically exclude IgE-mediated allergies, drug reactions, cofactor-dependent food allergy, NSAID hypersensitivity, and infections before labeling as primary or idiopathic MCAS. 2, 4, 6

Idiopathic MCAS

Diagnosis of exclusion when no trigger, mutation, or genetic trait is identified after comprehensive evaluation. 3, 7

First-Line Treatment

Initiate non-sedating H1 antihistamines (cetirizine, fexofenadine, loratadine) at 2-4 times the standard FDA-approved dose combined with H2 antihistamines (famotidine 20-40 mg twice daily). 1, 2, 3, 4

Approximately two-thirds of patients achieve complete or major symptom control with appropriate mediator-targeted therapy; one-third show only minor response and require combination regimens. 4

Complete symptom resolution occurs in roughly one-third of patients receiving first-line H1/H2 antihistamine combinations at 2-4 × standard doses. 4

Therapeutic response should be evaluated over 2-6 weeks before escalating therapy; lack of improvement indicates the need for additional interventions. 4

Common Causes of Apparent Treatment Resistance

Inadequate dosing: Using standard antihistamine doses instead of the guideline-recommended 2-4 × doses falsely suggests resistance 4

Premature escalation: Advancing therapy before a ≥1-month trial of cromolyn sodium at full dose (200 mg four times daily) 4

Misdiagnosis: Patients lacking the full triad of criteria, having chronic rather than episodic symptoms, or presenting with single-organ involvement 4

Second-Line and Add-On Therapies

Oral cromolyn sodium 200 mg four times daily for gastrointestinal symptoms; initiate at low dose and titrate upward over 1-2 weeks to improve tolerability. 1, 3, 4 A minimum of 1 month at full dose is required before efficacy can be judged 4

Leukotriene antagonists (montelukast 10 mg daily, zafirlukast, or zileuton) when urinary LTE4 is elevated or antihistamine response is suboptimal; particularly effective for dermatologic symptoms, bronchospasm, and gastrointestinal upset. 1, 3, 4

Aspirin 325-650 mg twice daily may reduce flushing and hypotensive episodes in patients with documented urinary 11β-PGF2α elevation; initiation must occur in a controlled setting due to risk of triggering mast cell degranulation. 1, 4

Systemic corticosteroids (prednisone ≈0.5 mg/kg/day, approximately 50 mg) with slow taper over 1-3 months for severe refractory disease. 1, 4

For procedures with prior mast cell activation, administer prednisone 50 mg at 13 hours, 7 hours, and 1 hour before the intervention. 4

Omalizumab for patients who remain symptomatic despite optimal mediator-targeted therapy, particularly effective in preventing recurrent anaphylaxis. 4

Advanced agents for clonal MCAS:

• Midostaurin (multikinase inhibitor) for advanced systemic mastocytosis with refractory symptoms; prophylactic ondansetron 30-60 minutes before dosing mitigates nausea 4
• Cytoreductive therapies (interferon-α, cladribine) for life-threatening manifestations unresponsive to antimediator drugs 3, 4

Emergency Management

All patients must carry two epinephrine auto-injectors (0.3 mg for adults); 20-50% of systemic mastocytosis patients experience systemic anaphylaxis, and MCAS patients have heightened risk. 3, 4

For anaphylaxis, immediately assume supine position, administer intramuscular epinephrine, and call emergency services. 2, 3

Use supplemental oxygen, IV fluids, and secondary management with chlorphenamine and hydrocortisone. 2

Perioperative Management

Premedicate with H1/H2 antihistamines plus corticosteroids before surgery, invasive procedures, or contrast imaging to prevent anaphylaxis. 4

Coordinate multidisciplinary care among surgical, anesthesia, and allergy teams, including review of prior anesthetic records and avoidance of known triggers. 4

Fentanyl or remifentanil are preferred opioid alternatives to morphine or codeine when opioid analgesia is required. 4

Untreated pain is a potent mast cell trigger; therefore, analgesics should not be withheld. 4

Trigger Avoidance

Identify and eliminate specific triggers including:

• Insect venoms (hymenoptera stings are well-documented triggers) 1, 2
• Temperature extremes 1
• Mechanical irritation and physical pressure 4
• Alcohol 1
• Certain medications 1

Physical triggers such as exercise, temperature extremes, and pressure are specifically highlighted as important to address. 4

Monitoring and Prognosis

For stable MCAS, perform routine history, physical examination, and laboratory testing every 6-12 months, or sooner if new clinical issues arise. 4

Evaluate symptom burden and quality of life with the Mast Cell Activation Symptom (MSAF) questionnaire and Mast Cell Quality of Life (MQLQ) questionnaire. 4

Monitor bone health with DEXA scan every 1-3 years for individuals with osteopenia or osteoporosis. 4

No progression to systemic mastocytosis was observed in a Mayo Clinic cohort of clonal MCAS patients followed >15 years. 3, 4

Patients with indolent systemic mastocytosis have normal life expectancy similar to the age-matched general population. 3

Referral Indications

Refer to a specialized mast cell disorder center for:

• Refractory disease requiring expert assessment 3, 4
• Access to advanced diagnostic assays (urinary mediators, sensitive KIT testing, tryptase genotyping) 4
• Enrollment in research studies 4
• Comprehensive evaluation when diagnosis remains uncertain 2, 4